EMTRICITABINE TENOFOVIR DISOPROXIL MYLAN 200 mg/245 mg, film-coated tablet 30 tablets, CIP 3400930254288
Active ingredients: Emtricitabine, Tenofovir disoproxil maleate, Tenofovir disoproxil
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tablets, CIP 3400930254288orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EMTRICITABINE TENOFOVIR DISOPROXIL MYLAN 200 mg/245 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 1 comprimé(s)
- Marketing authorisation holder
- MYLAN PHARMACEUTICALS (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 6 Aug 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65271985CIP73025428CIP133400930254288Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉNOFOVIR DISOPROXILcomprimé | 245 mg · un comprimé | FT |
| MALÉATE DE TÉNOFOVIR DISOPROXILcomprimé | — | SA |
| EMTRICITABINEcomprimé | 200 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.